Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7I1T9)

Drug Name

Balsalazide Drug Info

Synonyms

Balsalazida; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazide [INN:BAN]; Balsalazido; Balsalazido [Spanish]; Balsalazidum; Balsalazidum [Latin]; BX-661A; Colazide; BALSALAZIDE; P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 80573-04-2; C17H15N3O6; CHEBI:267413; UNII-P80AL8J7ZP

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Approved	[1]

Cross-matching ID

PubChem CID: 54585
ChEBI ID: CHEBI:267413
CAS Number: CAS 80573-04-2
TTD Drug ID: DM7I1T9
INTEDE Drug ID: DR2414

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[6]
Naproxen	DMZ5RGV	Bursitis		Approved	[7]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[8]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[9]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[10]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[11]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[12]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[11]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[13]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Azoreductase (azoR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CTK0H-9987	DMSGYNP	N. A.	N. A.	Phase 2	[15]
SC-47085	DMGH4Q0	N. A.	N. A.	Phase 2	[16]
CB1954	DMVP4YK	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[17]
Ipsalazide	DMYEM59	N. A.	N. A.	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Azoreductase (azoR)	DEEHWOG	AZOR_ECOLI	Substrate	[3]
FMN-dependent NADH-azoreductase (azoR1)	DETQAEP	AZOR1_PSEAE	Substrate	[4] , [5]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077806.
2	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
3	Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15.
4	Role of tyrosine 131 in the active site of paAzoR1, an azoreductase with specificity for the inflammatory bowel disease prodrug balsalazide. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jan 1;66(Pt 1):2-7.
5	Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol. 2014 Jun;171(11):2705-25.
6	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
7	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
10	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
13	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
14	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
15	The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica. 1971 Mar;1(2):143-56.
16	Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64.
17	Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol. 2010 Mar 1;79(5):678-87.